Is OPXA a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

544 people get OPXA articles and Market Currents by email alert.

Get email alerts on OPXA »

HEADLINES:

Opexa Therapeutics Reports First Quarter 2013 Financial Results and Provides Corporate Update

Business Wire (May 14, 2013)
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss First Quarter 2013 Financial Results

Business Wire (May 10, 2013)
Opexa Therapeutics to Present at the Regenerative Medicine - A Fundamental Shift in Science & Culture Conference

Business Wire (Apr 4, 2013)
Opexa Therapeutics Announces Changes to Senior Management Team

Business Wire (Apr 1, 2013)
Opexa Therapeutics Reports Year End 2012 Financial Results and Provides Corporate Update

Business Wire (Mar 28, 2013)
Chelsea Therapeutics: A Shoe-In For FDA Approval, Shares Could Double From Here
Shane Blackmon • Tue, Mar 26 • 11 Comments
Opexa: A Significant Growth Opportunity For Short-Term Traders And Long-Term Investors
Scott Matusow • Tue, Mar 26 • 29 Comments
Opexa Therapeutics Poised For Breakout
Tomas Leszczynski • Tue, Mar 12 • 8 Comments
Opexa Therapeutics to Present at the 6th Annual European Life Science CEO Forum

Business Wire (Mar 4, 2013)
Opexa Therapeutics Gets Attention From Institutions, Should It Get Yours?
Snefix • Thu, Feb 14 • 4 Comments
Opexa Therapeutics, Inc. Announces Pricing of Common Stock and Warrant Offering

Business Wire (Feb 7, 2013)
Opexa Therapeutics to Present at the 15th Annual BIO CEO & Investor Conference

Business Wire (Feb 7, 2013)
Opexa Rallies Bigtime On Deal With Merck Serono
Brian L. Wilson • Wed, Feb 6 • 7 Comments
Merck Serono and Opexa Therapeutics Enter into Option and License Agreement for Development of Tcelna™ (imilecleucel-T) for Treatment of Multiple Sclerosis

Business Wire (Feb 5, 2013)
How Individuals Can Gain An Advantage Over Institutional Investors
Robert Mann • Tue, Jan 29 • 5 Comments
Opexa Therapeutics Closes Private Note Offering

Business Wire (Jan 23, 2013)
Opexa Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement

Business Wire (Jan 15, 2013)
Opexa Therapeutics Reports Third Quarter 2012 Financial Results and Provides Corporate Update

Business Wire (Nov 14, 2012)
Opexa Receives Clinical Trial Approval From Health Canada for Novel T-Cell Therapy

Business Wire (Nov 13, 2012)
Opexa Therapeutics to Present at the Lazard Capital Markets 9th Annual Healthcare Conference

Business Wire (Nov 12, 2012)

To learn more about Seeking Alpha Pro, click here.

Opexa: A Significant Growth Opportunity For Short-Term Traders And Long-Term Investors
Scott Matusow • Tue, Mar 26 • 29 Comments
Opexa Therapeutics Poised For Breakout
Tomas Leszczynski • Tue, Mar 12 • 8 Comments
Opexa Therapeutics Gets Attention From Institutions, Should It Get Yours?
Snefix • Thu, Feb 14 • 4 Comments
Opexa Rallies Bigtime On Deal With Merck Serono
Brian L. Wilson • Wed, Feb 6 • 7 Comments

Chelsea Therapeutics: A Shoe-In For FDA Approval, Shares Could Double From Here
Shane Blackmon • Tue, Mar 26 • 11 Comments
How Individuals Can Gain An Advantage Over Institutional Investors
Robert Mann • Tue, Jan 29 • 5 Comments
Biotechs Treating Incurable Disease Warrant Early Look
Troy Bayer • Fri, Sep 14, 2012 • 8 Comments
3 Pharmaceutical Stocks Making Big Moves
Markus Aarnio • Tue, Jul 17, 2012 • 8 Comments
4 Small-Cap Pharma Stocks With Zero Debt To Consider Currently
Matt Schilling • Wed, Jul 11, 2012 • 8 Comments
Post Excessive Sell-Off, September Is Still In The Wind
Henry McCusker • Tue, Aug 30, 2011
6 Companies That Could Revolutionize Medicine -- And Portfolios
Michael J. Ray • Thu, Aug 18, 2011 • 8 Comments
5 Cheap Biotech Stocks That May Rebound Ahead of the Market
Rougemont • Fri, Aug 12, 2011 • 11 Comments
A Busy Week for Multiple Sclerosis News
Douglas Cress • Sun, Sep 26, 2010 • 4 Comments
Market Monday: Banking Bulls
Jason Cimpl • Mon, Sep 13, 2010
Stem Cell Competition Heating Up
Michael Becker • Wed, Aug 25, 2010 • 8 Comments
Closing Update: Stocks String Together 3 Straight Wins, Commodities Gain
Midnight Trader • Tue, Sep 8, 2009 • 4 Comments
Novartis: Powering into the Multiple Sclerosis Market
Richard Sater • Tue, Sep 8, 2009 • 3 Comments
Biotech Discounts Galore
The Burrill Report • Sun, Aug 9, 2009 • 1 Comment
24 Breakout Stocks on Big Volume
Option Maestro • Sun, Aug 9, 2009 • 6 Comments
Adult Stem Cell Drugs and Therapies Are the Next Big Market
M. E. Garza • Thu, Jun 18, 2009 • 15 Comments
Expecting Post-Stimulus Catalyst for Stem Cell Research Companies
Mike Havrilla • Mon, Feb 16, 2009 • 15 Comments
32 Stem Cell Companies to Watch
Mike Havrilla • Wed, Feb 4, 2009 • 11 Comments
Biotech Day In Review: Cell Genesys Climbs On GVAX Results
Centient Biotech Investor • Wed, Apr 4, 2007
Investing in Stem Cell Stocks: Growth Industry of the Future?
Stockerblog • Wed, Feb 21, 2007 • 13 Comments

There are no Transcripts on OPXA.

Opexa Therapeutics Reports First Quarter 2013 Financial Results and Provides Corporate Update

Business Wire (May 14, 2013)
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss First Quarter 2013 Financial Results

Business Wire (May 10, 2013)
Opexa Therapeutics to Present at the Regenerative Medicine - A Fundamental Shift in Science & Culture Conference

Business Wire (Apr 4, 2013)
Opexa Therapeutics Announces Changes to Senior Management Team

Business Wire (Apr 1, 2013)
Opexa Therapeutics Reports Year End 2012 Financial Results and Provides Corporate Update

Business Wire (Mar 28, 2013)
Opexa Therapeutics to Present at the 6th Annual European Life Science CEO Forum

Business Wire (Mar 4, 2013)
Opexa Therapeutics, Inc. Announces Pricing of Common Stock and Warrant Offering

Business Wire (Feb 7, 2013)
Opexa Therapeutics to Present at the 15th Annual BIO CEO & Investor Conference

Business Wire (Feb 7, 2013)
Merck Serono and Opexa Therapeutics Enter into Option and License Agreement for Development of Tcelna™ (imilecleucel-T) for Treatment of Multiple Sclerosis

Business Wire (Feb 5, 2013)
Opexa Therapeutics Closes Private Note Offering

Business Wire (Jan 23, 2013)
Opexa Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement

Business Wire (Jan 15, 2013)
Opexa Therapeutics Reports Third Quarter 2012 Financial Results and Provides Corporate Update

Business Wire (Nov 14, 2012)
Opexa Receives Clinical Trial Approval From Health Canada for Novel T-Cell Therapy

Business Wire (Nov 13, 2012)
Opexa Therapeutics to Present at the Lazard Capital Markets 9th Annual Healthcare Conference

Business Wire (Nov 12, 2012)
Opexa Announces Agreements for up to $16.5 Million in Equity Commitments

Business Wire (Nov 5, 2012)
Opexa to Participate at UBS Global Life Sciences Conference

Business Wire (Sep 17, 2012)
Opexa Initiates Late Stage Clinical Study of Tcelna in Patients with Secondary Progressive Multiple Sclerosis (SPMS)

Business Wire (Sep 12, 2012)
Opexa to Participate at Upcoming Industry Conferences

Business Wire (Sep 10, 2012)
Opexa Therapeutics Reports Second Quarter 2012 Financial Results and Provides Corporate Update

Business Wire (Aug 13, 2012)
Opexa Therapeutics Closes Secured Note Financing

Business Wire (Jul 26, 2012)

OPXA vs. ETF Alternatives

Company Description

Currently, there's no company description for OPXA.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, May 14, 1:01 PM Opexa (OPXA -18%) gets slammed today after posting a Q1 net loss of $0.58 per share, significantly wider than a year-ago, as operating expenses climbed. The company did manage to record $220K in revenue as part of its upfront payments from Merck Serono, versus no revenue during the year-ago quarter. There were no analyst estimates available for comparison. Comment! [Healthcare, Earnings, On the Move]
Tuesday, May 14, 12:45 PM Midday top 10 gainers: PDII +31%. UNTK +22%. ALIM +19%. SODA +15%. CHLN +15%. TEAR +14%. ESI +14%. ECTY +14%. BVSN +12%. RVLT 12%.
Midday top 10 losers: TELOZ -28%. OPXA -19%. SED -16%. STXS -14%. FMAR -13%. VELT -12%. TSRE -12%. TRMD -11%. CCCL -10%. PT -10%. Comment! [On the Move]
Monday, April 1, 10:52 AM Shares of Opexa Therapeutics (OPXA -5.6%) slides after reporting disappointing FY12 results late Thursday, just prior to the long weekend. The company posted a full year net loss of $8.9M versus a loss of $5.97M for 2011, due partly to increased research and other expenses. Additionally, this morning the drug developer announces some changes to its senior managment team, appointing Karthik Radhakrishnan as CFO, Kenny Frazier as VP of Clinical Development and Regulatory Affairs and Maryann Murray as Clinical Development Manager. Comment! [Healthcare, Earnings, On the Move]
Tuesday, March 26, 12:54 PM Midday top 10 gainers: PTEK +30%. BVX +23%. OPXA +20%. LEDS +20%. IBCP +13%. DXYN +11%. GTAT +11%. APP +11%. HGSH +9%. PGNX +9%.
Midday top 10 losers: ZIOP -62%. FUQI -17%. GMAN -16%. PGTI -14%. STSI -13%. GMXR -11%. STXS -11%. PRTS -10%. REED -10%. CSUN -8%. Comment! [On the Move]
Tuesday, March 26, 10:51 AM Shares of Opexa Therapeutics (OPXA +18%) spike higher today amid heavier-than-usual trading volumes. News is light, but the company's 10-K is due out tomorrow, and it could be the catalyst behind the move as investors are anticipating a number of developments in its pipeline. Additionally, an article in Seeking Alpha this morning says the stock is poised to break out for several reasons, citing the strength of its new partnership agreement with Merck Serono, new developments with its lead product candidate, Tcelna, and signs of a large, active institutional buyer in the market. 1 Comment [Healthcare, On the Move]
Tuesday, March 19, 1:00 PM Midday top 10 gainers: EFUT +53%. ATOS +29%. GST +20%. KYTH +14%. DWCH +10%. NPSP +9%. SHIP +9%. CSTE +8%. OPXA +8%. LTRX +8%.
Midday top 10 losers: AFFY -64%. MTSL -33%. HNR -33%. WSCI -23%. WAC -19%. INTX -19%. STSI -17%. TWER -14%. CLWT -13%. GMXR -13%. Comment! [On the Move]
Friday, March 1, 12:08 PM Opexa Therapeutics (OPXA +12%) moves up today after disclosing that Nasdaq regulators earlier this week agreed to postpone a possible delisting until May 15 after it files its quarterly report for the three months ending March 31. According to its regulatory filing, OPXA was given 45 days to present a plan to regain compliance. Comment! [Healthcare, On the Move]
Tuesday, February 12, 9:10 AM Premarket gainers: STEM +30%. ZIOP +14%. KORS +12%. MAS +8%. AVP +7%. HERO +7%. BCS +7%. GY +6%. OPXA +6%. GTE +5%.
Losers: MELA -17%. ORIG -5%. WNS -5%.
Comment! [On the Move]
Tuesday, February 5, 1:00 PM Midday top 10 gainers: OPXA +189%. CEP +31%. SCKT +23%. PLX +18%. CPSS +18%. VMED +17%. TRT +17%. STV +16%. BCOM +15%. CNR +15%.
Midday top 10 losers: DCIX -13%. IEC -13%. PRPH -11%. BIDU -11%. ACI -11%. PGRX -10%. JAXB -10%. DFZ -10%. RTEC -9%. SGMS -9%. Comment! [On the Move]
Tuesday, February 5, 9:24 AM Opexa Therapeutics (OPXA) +305% premarket on news it could be awarded up to $225M in a commercialization deal struck with Merck Serono for its multiple sclerosis therapy Tcelna. OPXA's lead product candidate is in Phase IIb trials in patients with secondary progressive MS, and has received FDA fast-track designation. Serono gains global development and commercial rights to Tcelna. 1 Comment [Healthcare, On the Move]
Friday, December 21, 2012, 12:45 PM Midday top 10 gainers: HALO +27%. CEMI +24%. ASCA +20%. FCFC +18%. PNK +17%. ABCD +14%. ATAI +12%. BONA +11%. WWAY +9%. IKAN +9%.
Midday top 10 Losers: CT -52%. ALX -26%. RIMM -21%. EDMC -19%. MSON -17%. ECTE -17%. HLF -14%. OPXA -13%. MHH -12%. AMPL -11%. 3 Comments [On the Move]
Tuesday, December 18, 2012, 12:45 PM Midday top 10 gainers: BOSC +83%. OPXA +31%. MEIP +30%. ARB +24%. RNIN +21%. VNDA +21%. III +18%. NVGN +16%. SNFCA +14%. GDP +14%.
Midday top 10 Losers: AWRE -23%. CNH -18%. LEI -17%. GALE -17%. LIVE -16%. CIS -14%. GTAT -13%. MNGA -12%. RCMT -12%. SWHC -10%. Comment! [On the Move]
Monday, December 17, 2012, 12:45 PM Midday top 10 gainers: GNVC +37%. CBOU +30%. HRT +16%. CEDC +15%. OCZ +13%. CPWR +13%. ONCY +13%. JVA +12%. VELT +12%. HTCH +12%.
Midday top 10 Losers: SCL -48%. GYRO -31%. END -20%. OPXA -13%. CLWR -12%. XUE -12%. SSE -11%. ALIM -11%. RVM -11%. NBG -9%. 1 Comment [On the Move]
Friday, September 7, 2012, 2:04 PM Opexa Therapeutics (OPXA +3.2%) trades up today after signing a sales agreement with Brinson Patrick Securities, under which the company may sell shares of its common stock, with Brinson Patrick Securities as its sales agent on a 3% commission. Comment! [Healthcare, On the Move]
Monday, August 13, 2012, 11:25 AM Opexa Therapeutics (OPXA -2.9%) trades lower after the company reported a deeper Q2 loss and issued an update on its quarterly corporate developments. Losses grew as R&D costs nearly doubled on the company's preparation for Phase II trials of its lead MS drug therapy Tcelna. Additionally, the company says it's closed financing of its $4.1M private offering, and appointed current board member David Jorden as CFO, effective August 15. Comment! [Healthcare, Earnings, On the Move]

Mongoose7916
$OPXA any bets it reverses tomorrow?
May 13, 2:42 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

sushifishman
Houstons Business Journal is reporting that $OPXA to begin PHASE III for RRMS Huge news. Two trials!
Mar 13, 12:12 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Justin M. Hall
Rx Investors' Cancer Vax Index ==> BPAX, BVTI, CLDX, DNDN, GNBT.OB, NWBO, VICL, ONTY, TRGNF, OPXA ==> http://bit.ly/bxkxgm/
10/1/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Drug Recruiter
GILD, NVS, SPPI, IMUC, LIXT, ACTC.OB, CYTX, CVM, DCTH, BOCX, AGEN, ACCP, CUR, CCEL.OB, CRIS, OPXA, CYTK, LGND, ISPH,
9/27/09
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

OTC PICKS
$OPXA UP AS MUCH AS 5.97% in morning trade, and $GDSM up as much as 5%
8/10/09
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

OPXA Opexa Therapeutics, Inc.

OPXA

Opexa Therapeutics, Inc.